<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p4" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_4{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_4{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_4{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_4{left:341px;bottom:30px;}
#t5_4{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_4{left:377px;bottom:30px;}
#t7_4{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_4{left:540px;bottom:30px;}
#t9_4{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_4{left:996px;bottom:873px;letter-spacing:-0.1px;}
#tb_4{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#tc_4{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#td_4{left:1091px;bottom:28px;letter-spacing:0.24px;}
#te_4{left:1092px;bottom:65px;letter-spacing:-0.11px;}
#tf_4{left:36px;bottom:778px;letter-spacing:-0.12px;word-spacing:0.02px;}
#tg_4{left:36px;bottom:299px;letter-spacing:-0.12px;word-spacing:0.02px;}
#th_4{left:35px;bottom:268px;letter-spacing:-0.13px;}
#ti_4{left:35px;bottom:250px;letter-spacing:-0.09px;word-spacing:0.01px;}
#tj_4{left:41px;bottom:232px;}
#tk_4{left:58px;bottom:232px;letter-spacing:-0.09px;}
#tl_4{left:63px;bottom:213px;}
#tm_4{left:76px;bottom:213px;letter-spacing:-0.09px;}
#tn_4{left:41px;bottom:195px;}
#to_4{left:58px;bottom:195px;letter-spacing:-0.1px;}
#tp_4{left:63px;bottom:177px;}
#tq_4{left:76px;bottom:177px;letter-spacing:-0.09px;}
#tr_4{left:36px;bottom:748px;letter-spacing:-0.12px;word-spacing:0.02px;}
#ts_4{left:36px;bottom:549px;letter-spacing:-0.25px;}
#tt_4{left:36px;bottom:531px;}
#tu_4{left:46px;bottom:531px;letter-spacing:-0.09px;word-spacing:-0.08px;}
#tv_4{left:823px;bottom:531px;letter-spacing:-0.1px;}
#tw_4{left:896px;bottom:531px;letter-spacing:-0.13px;word-spacing:0.05px;}
#tx_4{left:47px;bottom:512px;letter-spacing:-0.1px;}
#ty_4{left:47px;bottom:494px;letter-spacing:-0.09px;word-spacing:-0.01px;}
#tz_4{left:47px;bottom:476px;letter-spacing:-0.13px;word-spacing:0.04px;}
#t10_4{left:36px;bottom:457px;letter-spacing:-0.25px;}
#t11_4{left:36px;bottom:439px;letter-spacing:-0.09px;}
#t12_4{left:47px;bottom:421px;letter-spacing:-0.1px;}
#t13_4{left:47px;bottom:402px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t14_4{left:36px;bottom:384px;letter-spacing:-0.15px;word-spacing:0.06px;}
#t15_4{left:36px;bottom:366px;}
#t16_4{left:46px;bottom:366px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t17_4{left:47px;bottom:347px;letter-spacing:-0.09px;}
#t18_4{left:346px;bottom:347px;letter-spacing:-0.09px;}
#t19_4{left:804px;bottom:347px;letter-spacing:-0.09px;}
#t1a_4{left:923px;bottom:347px;letter-spacing:-0.08px;}
#t1b_4{left:47px;bottom:329px;letter-spacing:-0.15px;word-spacing:0.05px;}
#t1c_4{left:276px;bottom:329px;letter-spacing:-0.09px;}
#t1d_4{left:632px;bottom:329px;letter-spacing:-0.09px;}
#t1e_4{left:1070px;bottom:329px;}
#t1f_4{left:36px;bottom:579px;letter-spacing:-0.12px;word-spacing:0.02px;}
#t1g_4{left:35px;bottom:718px;letter-spacing:-0.23px;word-spacing:0.14px;}
#t1h_4{left:35px;bottom:700px;}
#t1i_4{left:46px;bottom:700px;letter-spacing:-0.09px;}
#t1j_4{left:46px;bottom:682px;letter-spacing:-0.08px;}
#t1k_4{left:41px;bottom:663px;}
#t1l_4{left:58px;bottom:663px;letter-spacing:-0.12px;word-spacing:-0.02px;}
#t1m_4{left:57px;bottom:645px;letter-spacing:-0.09px;}
#t1n_4{left:35px;bottom:627px;letter-spacing:-0.12px;}
#t1o_4{left:35px;bottom:608px;}
#t1p_4{left:46px;bottom:608px;letter-spacing:-0.09px;}
#t1q_4{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_4{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_4{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_4{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_4{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s4_4{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s5_4{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.s6_4{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.s7_4{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s8_4{font-size:17px;font-family:Webdings_k6;color:#000;}
.s9_4{font-size:17px;font-family:ArialMT_k0;color:#000;}
.sa_4{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.sb_4{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.sc_4{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts4" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg4Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg4" style="-webkit-user-select: none;"><object width="1210" height="935" data="4/4.svg" type="image/svg+xml" id="pdf4" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_4" class="t s0_4">NCCN Guidelines Version 4.2024 </span>
<span id="t2_4" class="t s0_4">Head and Neck Cancers </span>
<span id="t3_4" class="t s1_4">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_4" class="t s2_4">® </span>
<span id="t5_4" class="t s1_4">(NCCN </span>
<span id="t6_4" class="t s2_4">® </span>
<span id="t7_4" class="t s1_4">), All rights reserved. NCCN Guidelines </span>
<span id="t8_4" class="t s2_4">® </span>
<span id="t9_4" class="t s1_4">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_4" class="t s3_4">NCCN Guidelines Index </span>
<span id="tb_4" class="t s3_4">Table of Contents </span>
<span id="tc_4" class="t s3_4">Discussion </span>
<span id="td_4" class="t s4_4">UPDATES </span>
<span id="te_4" class="t s5_4">Continued </span>
<span id="tf_4" class="t s6_4" data-mappings='[[60,"fi"]]'>Terminologies in all NCCN Guidelines are being actively modiﬁed to advance the goals of equity, inclusion, and representation. </span>
<span id="tg_4" class="t s4_4">Updates in Version 2.2024 of the NCCN Guidelines for Head and Neck Cancers from Version 1.2024 include: </span>
<span id="th_4" class="t s5_4">NASO-B </span>
<span id="ti_4" class="t s7_4">• Recurrent, Unresectable, Oligometastatic, or Metastatic Disease (with no surgery or RT option) </span>
<span id="tj_4" class="t s8_4"></span><span id="tk_4" class="t s9_4" data-mappings='[[10,"fi"]]'>Preferred ﬁrst-line regimen added: Cisplatin/gemcitabine + toripalimab-tpzi (category 1) </span>
<span id="tl_4" class="t sa_4">◊ </span><span id="tm_4" class="t s7_4">Reference added: Mai H, et al. [abstract] J Clin Oncol. 2023;41:16_suppl, 6009 </span>
<span id="tn_4" class="t s8_4"></span><span id="to_4" class="t s9_4">Preferred subsequent-line regimen added: Toripalimab-tpzi (if disease progression on or after platinum-containing therapy) </span>
<span id="tp_4" class="t sa_4">◊ </span><span id="tq_4" class="t s7_4">Reference added: Mai H, et al. Nat Med. 2021;27:1536-1543 </span>
<span id="tr_4" class="t s4_4">Updates in Version 4.2024 of the NCCN Guidelines for Head and Neck Cancers from Version 3.2024 include: </span>
<span id="ts_4" class="t s5_4">ORPHPV-1 </span>
<span id="tt_4" class="t s7_4">• </span><span id="tu_4" class="t s9_4" data-mappings='[[15,"fi"]]'>Footnote s modiﬁed: Adverse pathologic features: extranodal extension, positive margins, close margins </span><span id="tv_4" class="t sb_4">(&lt;3 mm), </span><span id="tw_4" class="t s7_4">pT3 or pT4 primary, one positive </span>
<span id="tx_4" class="t s9_4" data-mappings='[[142,"fi"]]'>node &gt;3 cm or multiple positive nodes, nodal disease in levels IV or V, perineural invasion, vascular invasion, and lymphatic invasion. The deﬁnition </span>
<span id="ty_4" class="t s9_4">of an adverse pathologic feature in the context of HPV+ disease is an area of active research. This includes the presence and extent of extranodal </span>
<span id="tz_4" class="t s7_4">extension, and the number of involved nodes. (Also for ORPHPV-2, ORPHPV-3, ORPHPV-4, and footnote 14 on ORPH-A 2 of 2) </span>
<span id="t10_4" class="t s5_4">ORPHPV-2 </span>
<span id="t11_4" class="t s7_4">• Footnote added: De-escalation to 50 Gy may be considered in patients with p16 (HPV)-positive oropharynx cancer who have up to 4 positive lymph </span>
<span id="t12_4" class="t s9_4">nodes, T1–T2 resected to negative or close margins (&lt;3 mm), and/or N1–N2 disease (excluding bilateral disease based on ECOG 3311 criteria) with ≤1 </span>
<span id="t13_4" class="t s7_4">mm extranodal extension (Ferris et al 2022 JCO) (category 2B). (Also for ORPHPV-3) </span>
<span id="t14_4" class="t s5_4">ORPH-A (2 of 2) </span>
<span id="t15_4" class="t s7_4">• </span><span id="t16_4" class="t s9_4" data-mappings='[[48,"fi"]]'>PTV, low to intermediate risk, sub-bullet 2 modiﬁed: De-escalation to 50 Gy may be considered in patients with p16 (HPV)-positive oropharynx cancer </span>
<span id="t17_4" class="t s7_4">who have up to 4 positive lymph nodes, </span><span id="t18_4" class="t sb_4">T1-T2 resected to negative or close margins (&lt;3 mm), and/or </span><span id="t19_4" class="t s7_4">N1–N2 disease </span><span id="t1a_4" class="t sb_4">(excluding bilateral disease </span>
<span id="t1b_4" class="t sb_4">based on ECOG 3311 criteria) </span><span id="t1c_4" class="t s9_4">with ≤1 mm extranodal extension (category 2B) </span><span id="t1d_4" class="t s7_4">, or cT1–T2 resected to negative or close margins (&lt;3 mm) </span><span id="t1e_4" class="t s7_4">. </span>
<span id="t1f_4" class="t s4_4">Updates in Version 3.2024 of the NCCN Guidelines for Head and Neck Cancers from Version 2.2024 include: </span>
<span id="t1g_4" class="t s5_4">SYST-A (2 of 4) </span>
<span id="t1h_4" class="t s7_4">• </span><span id="t1i_4" class="t s9_4">Useful in Certain Circumstances, regimen added: Fam-trastuzumab deruxtecan-nxki (for HER2+ (IHC 3+) solid tumors; subsequent line only with no </span>
<span id="t1j_4" class="t s7_4">satisfactory alternative treatment options) (category 2B) </span>
<span id="t1k_4" class="t s8_4"></span><span id="t1l_4" class="t s9_4" data-mappings='[[77,"ffi"]]'>Supporting reference added: 62 Meric-Bernstam F, Makker V, Oaknin A, et al. Eﬃcacy and safety of trastuzumab deruxtecan in patients with her2- </span>
<span id="t1m_4" class="t s7_4">expressing solid tumors: Primary results from the destiny-pantumor02 phase ii trial. J Clin Oncol 2024;42:47-58. </span>
<span id="t1n_4" class="t s5_4">MS-1 </span>
<span id="t1o_4" class="t s7_4">• </span><span id="t1p_4" class="t s9_4" data-mappings='[[45,"fl"]]'>The discussion section has been updated to reﬂect the changes in the algorithm. </span>
<span id="t1q_4" class="t sc_4">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
